Introduction
Bromocriptine has been used extensively in the treatment of acromegaly since this application was introduced by Liuzzi et al. (1974) and Thorner et al. (1975) . In this condition it is believed to act by suppressing the secretion or release of growth hormone (GH). Data on the relation of the dose of bromocriptine to the suppression of GH are limited (Wass et al. 1977) . We describe here the effect of bromocriptine in total daily doses of 10, 20, 30 and 40 mg on plasma GH levels, measured during an oral glucose tolerance test in cases of acromegaly, in order to establish the minimum effective dose in this condition.
Methods
Nineteen acromegalic patients (10 male), with an age range of 33-70 years, were studied. The duration of disease since diagnosis ranged from one month to 12 years. Six patients had not been treated previously. In the remainder, treatment had been as follows: radiotherapy in 3; cryosurgery in 2; yttrium implantation in 2; transfrontal craniotomy and tumour removal in 1; and the same operation followed by radiotherapy to the pituitary gland in 5.
Plasma GH (gg/l) was measured by a double antibody radioimmunoassay technique. Blood samples were taken during a 50 g oral glucose tolerance test (OGTT), the patient remaining at rest throughout. Preliminary studies confirmed that the mean of the fasting and 3-hour plasma GH levels in a 5-hour OGTT did not differ significantly from the mean of the fasting and subsequent plasma GH levels taken at half-hour intervals throughout the test. Thus plasma GH was measured when fasting and resting and 3 hours after the 50 g oral glucose load, and a mean value was obtained (mean of 0 and 3-hour plasma GH).
The plasma GH level was measured in this way in each patient before starting treatment with bromocriptine, and while taking total daily doses of 10, 20, 30 and 40 mg in divided doses 6hourly. The doses were increased gradually over 2 weeks and maintained at the test level for at least one week before each OGTT.
Patients were assessed clinically with regard to certain symptoms (headache, sweating, paraesthesiae, libido, and well-being) and objective signs (facies, shoe size, hand volume, and skin fold thickness) before starting bromocriptine and at each dose level.
Results
All plasma GH values refer to the mean of the 0 and 3-hour plasma GH levels. There was a wide scatter of absolute values, so for interpatient comparison percentage changes have been used. In Figure 1 the percentage change in plasma GH from the pretreatment level at each dose of bromocriptine has been plotted for each of the 19 patients.
The overall mean percentage change in plasma GH from the pretreatment level was calculated for all 19 patients at the 4 dose levels of bromocriptine. The mean percentage falls in plasma GH were: at 10 mg bromocriptine, 31.8% (P<0.01); at 20 mg, 37.8% (P<0.01); at 30 mg, 37.1% (P<0.05); and at 40 mg, 42.5% (P < 0.01). The P values refer to Wilcoxon's test of the significance of paired differences. Thus the mean percentage fall in plasma GH at each dose level of bromocriptine compared with the pretreatment level was statistically significant. The progressive fall in mean plasma GH achieved by increasing the dose of bromocriptine is analysed in Table 1 . Using Wilcoxon's test of the significance of paired differences, the fall in mean plasma GH produced by the 10 mg dose of bromocriptine is statistically significant at the 1% level, but the additional mean percentage fall when the dose was increased to 20 mg failed to reach statistical significance (0.1 > P >O.05). Further mean falls when the dose was increased to 30 mg and then to 40 mg daily did not achieve statistical significance. A maintenance dose of bromocriptine was chosen on the basis of the percentage fall in plasma GH together with the clinical response. In Figure 2 the plasma GH levels are plotted against the dose of bromocriptine for the 15 patients whose plasma GH levels fell. In 13 patients this fall was achieved on a daily dose of 10 mg or 20 mg bromocriptine, and 9 of these 13 patients showed clinical improvement. In 2 patients plasma GH fell only when the dose was raised to 30 mg and 40 mg, and both showed clinical improvement. Three of the 4 patients without a fall in plasma GH while on bromocriptine improved clinically. Neither clinical response nor fall in GH related to whether or not the patient had previously received treatment for the pituitary disorder.
Discussion
This study demonstrates a dose-response relationship between the fall in plasma GH and increased doses of bromocriptine in acromegalic patients: the optimum daily dose for general use should be 20 mg. Further slight falls in plasma GH when the daily dose was increased to 30 mg and 40 mg are not statistically significant. In the 2 patients in whom the dosage was maintained at a higher level the indication for this was clinical improvement.
It is important to establish an optimum dosage for bromocriptine in acromegaly in view of the expense of the drug, the short-term side effects, and the unknown hazards of long-term usage. During this study, at one dose level or another, 14 patients had transient nausea and anorexia, and postural hypotension, but the only chronic side effect was constipation in 9 patients. Only one patient was free of side effects throughout.
Using day-time profiles of GH, Wass and colleagues (1977) gave doses of between 10 and 60 mg of bromocriptine per day to produce maximal suppression of serum GH. Commonly the optimum dose lay between 20 and 40 mg per day. Increasing the dose above 20 mg was described as 'producing further improvement in mean growth hormone levels in 12 of 21 patients'. These workers also noted that while 58 oftheir 73 patients showed a significant fall in serum growth hormone levels during treatment, 71 improved symptomatically. In the present study, 3 of the 19 patients derived clinical benefit without a fall in plasma GH.
Summary
A study to establish the minimum dose of bromocriptine to suppress plasma growth hormone effectively and consistently in acromegalic patients is described. The optimum dose for general use is 20 mg per day in 4 divided doses. Treatment was not maintained above this level unless added clinical benefit resulted. Clinical improvement may, however, occur without significant changes in the plasma growth hormone level.
